{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:00:58Z","timestamp":1789210858954,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P50-MH100031"],"award-info":[{"award-number":["P50-MH100031"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH0977669"],"award-info":[{"award-number":["R01 MH0977669"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH101472"],"award-info":[{"award-number":["R01 MH101472"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01-MH046729"],"award-info":[{"award-number":["R01-MH046729"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01-MH081884"],"award-info":[{"award-number":["R01-MH081884"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.biopsych.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T23:13:18Z","timestamp":1517353998000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response"],"prefix":"10.1016","volume":"84","author":[{"given":"Thaddeus S.","family":"Block","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ned","family":"Kalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Belanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Schatzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2018.01.008_bib1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1176\/appi.ajp.159.11.1855","article-title":"Prevalence of depressive episodes with psychotic features in the general population","volume":"159","author":"Ohayon","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Perala","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1176\/appi.ajp.160.3.574","article-title":"Psychotic depression and mortality","volume":"160","author":"Vythilingam","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1176\/ajp.149.6.733","article-title":"Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV?","volume":"149","author":"Schatzberg","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0006-3223(87)90126-0","article-title":"Urinary free cortisol in psychotic depression","volume":"22","author":"Anton","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/archpsyc.57.8.755","article-title":"24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression","volume":"57","author":"Posener","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1176\/ajp.140.1.88","article-title":"The dexamethasone suppression test: Identification of substypes of depression","volume":"140","author":"Schatzberg","year":"1983","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib8","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1176\/ajp.154.11.1497","article-title":"DST studies in psychotic depression: A meta-analysis","volume":"154","author":"Nelson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-3956(85)90068-8","article-title":"A\u00a0corticosteroid\/dopamine hypothesis for psychotic depression and related states","volume":"19","author":"Schatzberg","year":"1985","journal-title":"J\u00a0Psychiatry Res"},{"key":"10.1016\/j.biopsych.2018.01.008_bib10","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2018.01.008_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.008_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/01.jcp.0000130557.08996.7a","article-title":"A\u00a0double-blind, randomized study of olanzapine and olanzapine\/fluoxetine combination for major depression with psychotic features","volume":"24","author":"Rothschild","year":"2004","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.008_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/JCP.0b013e3182239191","article-title":"Efficacy and safety of mifepristone for the treatment of psychotic depression","volume":"31","author":"Blasey","year":"2011","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.008_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00004714-200110000-00009","article-title":"Rapid reversal of psychotic major depression using mifepristone","volume":"21","author":"Belanoff","year":"2001","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.008_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2014.916414","article-title":"Anna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression","volume":"16","author":"Schatzberg","year":"2015","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4088\/JCP.v66n0509","article-title":"An 8-week open label trial of a 6-day course of mifepristone for the treatment of psychotic depression","volume":"66","author":"Simpson","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.npp.1300884","article-title":"Clinical and biological effects of mifepristone treatment for psychotic depression","volume":"31","author":"Flores","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2018.01.008_bib18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.biopsych.2006.05.034","article-title":"Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression","volume":"60","author":"DeBattista","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.cct.2009.03.001","article-title":"A\u00a0multisite trial of mifepristone for the treatment of psychotic depression: A site-by-treatment interaction","volume":"30","author":"Blasey","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.biopsych.2018.01.008_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2174\/1573400511309020009","article-title":"Trough plasma concentrations of mifepristone correlate with psychotic symptom reductions: A review of three randomized clinical trials","volume":"9","author":"Blasey","year":"2013","journal-title":"Curr Psychiatry Rev"},{"key":"10.1016\/j.biopsych.2018.01.008_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JCP.0000000000000744","article-title":"Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression","volume":"37","author":"Block","year":"2017","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2018.01.008_bib22","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.biopsych.2018.01.008_bib23","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials a meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1176\/ajp.132.7.716","article-title":"Depression, delusions, and drug response","volume":"132","author":"Glassman","year":"1975","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4088\/JCP.11r07324","article-title":"Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment","volume":"73","author":"Farahani","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2018.01.008_bib26","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1172\/JCI79828","article-title":"Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals","volume":"125","author":"Vendruscolo","year":"2015","journal-title":"J\u00a0Clin Invest"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322318300350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322318300350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:49:05Z","timestamp":1782827345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322318300350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0006322318300350"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2018.01.008","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}